Techniques in Regional Anesthesia & Pain Management
Volume 14, Issue 1 , Pages 10-18 , January 2010

Intrathecal analgesia in cancer pain

  • Marco R. Perez, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Marco R. Perez, MD, Department of Pain Medicine, University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Unit 409, Houston, TX 77030
    • ,
  • Steven C. Pulley, MD

References 

  1. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: A systematic review of the past 40 years. Ann Oncol. 2007;18:1437–1449
  2. World Health Organization. Cancer pain relief Geneva, WHO 1986. Anesth Analg. 1988;67:1159–1161
  3. Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines; a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain. 2001;93:247–257
  4. Miguel R. Interventional treatment of cancer pain: The fourth step in the WHO analgesic ladder?. Cancer Control. 2000;7:149–156
  5. Krames ES. Interventional pain management: Appropriate when less invasive therapies fail to provide adequate analgesia. Med Clin North Am. 1999;83:787–808
  6. Waldman SD. The role of spinal opiates in the management of cancer pain. J Pain Symptom Manage. 1990;5:163
  7. Smith TJ, Coyne PJ, Staats PS, et al. An implantable drug delivery system for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management. Ann Oncol. 2005;16:825–833
  8. Onofrio BM. Treatment of chronic pain of malignant origin with intrathecal opiates. Clin Neurosurg. 1983;31:304–315
  9. Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979;50:149–151
  10. Rauck RL, Cherry D, Boyer MF, et al. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain. 2003;4:441–447
  11. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20:4040–4049
  12. Coda BA, Brown MC, Schaffer R, et al. Pharmacology of epidural fentanyl, alfentanil, and sufentanil in volunteers. Anesthesiology. 1994;81:1149–1161
  13. Jacobson L, Chabal C, Brody MC, et al. Intrathecal methadone: A dose-response study and comparison with intrathecal morphine 0.5 mg. Pain. 1990;43:141–148
  14. Deer T, Krames ES, Hassenbusch SJ, et al. Polyanalgesic Consensus Conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: Report of an Interdisciplinary Expert Panel. Neuromodulation. 2007;10:300–328
  15. Deer TR, Caraway DL, Kim CK, et al. Clinical experience with intrathecal bupivacaine in combination with opiate for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J. 2002;2:274–278
  16. Walker SM, Goudas LC, Cousins MF, et al. Combination spinal analgesic chemotherapy: A systematic review. Anesth Analg. 2002;95:674–715
  17. Eisenach JC, DuPen S, Dubois M, et al. ; The Epidural Clonidine Study Group: Epidural clonidine analgesia for intractable cancer pain. Pain. 1995;61:391–399
  18. Hassenbusch SJ, Gunes S, Wachsman S, et al. Intrathecal clonidine in the treatment of intractable pain: A phase I/II study. Pain Med. 2002;3:85–91
  19. Stats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in treatment of refractory pain in patients with cancer or AIDS: A randomized controlled trial. JAMA. 2004;291:63–70
  20. Almeida RA, Lauretti GR, Mattos AL. Antinociceptive effect of low-dose intrathecal neostigmine combined with intrathecal morphine following gynecologic surgery. Anesthesiology. 2003;98:495–498
  21. Grant GJ, Piskoun B, Bansinath M. Intrathecal administration of liposomal neostigmine prolongs analgesia in mice. Acta Anaesthesiol Scand. 2002;46:90–94
  22. Yaksh TL, Noueihed R. The physiology and pharmacology of spinal opiates. Annu Rev Pharmacol Toxicol. 1985;25:433
  23. Zieglgansberger W. Opiate actions on mammalian spinal neurons. Int Rev Neurobiol. 1984;25:243
  24. Sakurada T, Komatsu T, Sakurada S. Mechanisms of nociception evoked by intrathecal high dose morphine. Neurotoxicology. 2005;26:801–809
  25. Terenius L. Characteristics of the “receptor” for narcotic analgesics in synaptic plasma membrane fractions from rat brain. Acta Pharmacol Toxicol. 1973;33:377–384
  26. Max MB, Inturrisi CE, Kaiko RF, et al. Epidural and intrathecal opiates: CSF and plasma profiles in patients with chronic cancer pain. Clin Pharmacol Ther. 1985;38:631
  27. Gustaffson LL, Schildt B, Jacobsen K. Adverse effects of extradural and intrathecal opiates: Report of a nationwide survey in Sweden. Br J Anaesth. 1982;54:479–486
  28. Kafer ER, Brown JT, Scott D. Biphasic depression of ventilatory responses to CO2 following epidural morphine. Anesthesiology. 1983;58:418–427
  29. Johansen MJ, Satterfield WC, Baze WB, et al. Continuous intrathecal infusion of hydromorphone: Safety in the sheep model and clinical implications. Pain Med. 2004;5:14–25
  30. Miguel R, Barlow I, Morrell M, et al. A prospective, randomized double blind comparison of epidural and intravenous sufentanil infusions. Anesthesiology. 1994;81:346–352
  31. Waara-Wolleat KL, Hildebrand KR, Stewart GR. A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. Pain Med. 2006;7:251–259
  32. Chan J, Heilpern G, Packham I, et al. A prospective randomized double blind trial use intrathecal fentanyl patients undergoing lumbar spinal surgery. Spine. 2006;31:2529–2533
  33. Mironer YE, Tollison CD. Methadone in the intrathecal treatment of chronic nonmalignant pain resistant to other neuroaxial agents: The first experience. J Int Neuromod Soc. 2001;4:25–31
  34. Hildebrand K, Elsberry D, Deer T. Stability, compatibility, and safety of intrathecal bupivacaine administered chronically via an implantable delivery system. Clin J Pain. 2001;17:239–244
  35. van Dongen RT, Crul BJ, De Bock M. Long-term intrathecal infusion of morphine and morphine/bupivacaine mixtures in the treatment of cancer pain: A retrospective analysis of 51 cases. Pain. 1993;55:119–123
  36. van Dongen RT, Crul BJ, van Egmond J. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain. 1999;15:166–172
  37. Deer T, Caraway DL, Kim CK, et al. Clinical experience with intrathecal bupivicaine in combination with opiate for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J. 2002;2:274–278
  38. Olivera B, Gray WR, Zeikus R, et al. Peptide neurotoxins from fish-hunting cone snails. Science. 1985;230:1338–1343
  39. Wallace M, Charapata S, Fisher R, et al. Ziconotide non-malignant pain study 96-002 group (Intrathecal ziconotide treatment chronic non-malignant pain: A randomized double blind placebo controlled). Neuromodulation. 2006;9:75
  40. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: A randomized controlled trial. JAMA. 2004;291:63–70
  41. Rauck RL, Wallace MS, Leong MS. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31:393–406
  42. Taricco M, Pagliacci MC, Telaro E, et al. Pharmacological interventions for spasticity following spinal cord injury: Results of a Cochrane systematic review. Eura Medicophys. 2006;42:5–15
  43. Rushman S, McLaren I. Management of intrathecal baclofen overdose. Intensive Care Med. 1999;25:239
  44. Ono H, Mishima A, Ono S, et al. Inhibitory effects of clonidine and tizanidine on release of substance P from slices of rat spinal cord and antagonism by alpha-adrenergic receptor antagonists. Neuropharmacology. 1991;30:585–589
  45. Wallace M, Yaksh TL. Long term spinal analgesic delivery: A review of the preclinical and clinical literature. Reg Anesth Pain Med. 2000;25:117–157
  46. Coombs DW, Saunders RL, Fratkin JD, et al. Continuous intrathecal hydromorphone and clonidine for intractable cancer pain. J Neurosurg. 1986;64:890–894
  47. Rudich Z, Peng P, Dunn E. Stability of clonidine in clonidine-hydromorphone mixture from implanted intrathecal infusion pumps in chronic pain patients. J Pain Symptom Manage. 2004;28:599–602
  48. Chen S, Khan GM, Pan H. Antiallodynic effect of intrathecal neostigmine is mediated by spinal nitric oxide in a rat model of diabetic neuropathic pain. Anesthesiology. 2001;95:1007–1012
  49. Hood DD, Eisenach JC, Tuttle R. Phase I safety assessment of intrathecal neostigmine methylsulfate in humans. Anesthesiology. 1995;82:331–345
  50. Kekesi G, Dobos I, Benedek G, et al. The antinociceptive potencies and interactions of endogenous ligands during continuous intrathecal administration: Adenosine, agmatine, and endomorphin-1. Anesth Analg. 2004;98:420–426
  51. Rane K, Segerdahl M, Goiny M, et al. Intrathecal adenosine administration: A phase 1 clinical safety study in healthy volunteers, with additional evaluation of its influence on sensory thresholds and experimental pain. Anesthesiology. 1998;89:1108–1115
  52. Belfrage M, Segerdahl M, Arnér S, et al. The safety and efficacy of intrathecal adenosine in patients with chronic neuropathic pain. Anesth Analg. 1999;89:136
  53. Rane K, Segerdahl M, Karlsten R. Intrathecal adenosine increases spinal cord blood flow in the rat: Measurements with the laser-Doppler flowmetry technique. Acta Anaesthesiol Scand. 2004;48:1249–1255
  54. Smiley MM, Lu Y, Vera-Portocarrero LP, et al. Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. Anesthesiology. 2004;101:759–765
  55. Lin JA, Lee MS, Wu CT, et al. Attenuation of morphine tolerance by intrathecal gabapentin is associated with suppression of morphine-evoked excitatory amino acid release in the rat spinal cord. Brain Res. 2005;1054:167–173
  56. Korkmaz HA, Maltepe F, Erbayraktar S, et al. Antinociceptive and neurotoxicologic screening of chronic intrathecal administration of ketorolac tromethamine in the rat. Anesth Analg. 2004;98:148–152
  57. Canavero S, Bonicalzi V, Clemente M. No neurotoxicity from long-term (> 5 years) intrathecal infusion of midazolam in humans. J Pain Symptom Manage. 2006;32:1–3
  58. Cao JL, Ding HL, He JH, et al. The spinal nitric oxide involved in the inhibitory effect of midazolam on morphine-induced analgesia tolerance. Pharmacol Biochem Behav. 2005;80:493–503
  59. Rainov NG, Heidecke V, Burkert W. Long-term intrathecal infusion of drug combinations for chronic back and leg pain. J Pain Symptom Manage. 2001;22:862–871
  60. Classen AM, Wimbish GH, Kupiec TC. Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system. J Pain Symptom Manage. 2004;28:603–611
  61. Hildebrand KR, Elsberry DD, Deer TR. Stability, compatibility, and safety of intrathecal bupivacaine administered chronically via an implantable delivery system. Clin J Pain. 2001;17:239–244
  62. Trissel LA. Trissels's Stability of Compounded Formulations. 2nd ed.. Washington, DC: APHA Publications; 2000;
  63. Shields D, Montenegro R. Chemical stability of ziconitide/clonidine hydrochloride admixtures with and without morphine sulfate during stimulated intrathecal administration. Neuromodulation. 2007;10(suppl):6–11
  64. Shields D, Montenegro R, Aclan J. Chemical stability of an admixture combining ziconotide and bupivacaine during simulated intrathecal administration. Neuromodulation. 2007;10(suppl):1–5
  65. Shields D, Montenegro R, Aclan J. Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation. 2007;10(suppl):12–17
  66. Practice guidelines for cancer pain management (A report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section). Anesthesiology. 1996;84:1243–1257
  67. Burton A, Rajagopal A, Shah H, et al. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med. 2004;5:239–247
  68. Bedder MD, Burchiel K, Larson A. Cost analysis of two narcotic delivery systems. J Pain Symptom Manage. 1991;6:368
  69. Hassenbusch SJ. Cost modeling for alternative routes of administration of opioids for cancer pain. Oncology. 1999;13:63–67
  70. Burton AW, Gassenbusch SJ. The double catheter technique for intrathecal medication trial: A brief clinical note and report of five cases. Pain Med. 2001;2:352–354
  71. Katz N. The impact of pain management on quality of life. J Pain Symptom Manage. 2002;24:S38–S47
  72. Turner JA, Sears JM, Loeser JD. Programmable intrathecal opioid delivery systems for chronic non-malignant pain: A systematic review of effectiveness and complications. Clin J Pain. 2007;23:180–195
  73. Boviatsis EJ, Kouyialis AT, Boutsikakis I, et al. Infected CNS infusion pumps (Is there a chance for treatment without removal?). Acta Neurochir (Wien). 2004;146:463–467
  74. Naumann C, Erdine S, Koulousakis A, et al. Drug adverse events and system complications of intrathecal opioid delivery for pain: Origins, detection, manifestations, and management. Neuromodulation. 1999;2:92–107
  75. Jones RL, Rawlins PK. The diagnosis of intrathecal infusion pump system failure: A focused review. Pain Physician. 2005;8:291–296
  76. Deer TR. A prospective analysis of intrathecal granuloma in chronic pain patients: A review of the literature and report of a surveillance study. Pain Physician. 2004;7:225–228
  77. Coffey RJ, Burchiel K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: Report and observations on 41 patients. Neurosurgery. 2002;50:78–86
  78. Deer TR, Raso LJ, Garten TG. Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: A report of two cases and a review of the identification and treatment of the complication. Pain Med. 2007;8:259–262
  79. Yaksh TL, Hassenbusch S, Burchiel K, et al. Inflammatory masses associated with intrathecal drug infusion: A review of preclinical evidence and human data. Pain Med. 2002;3:300–312
  80. Smith HS, Deer TE, Staats PS, et al. Intrathecal drug delivery. Pain Physician. 2008;11:S89–S104

PII: S1084-208X(09)00117-7

doi: 10.1053/j.trap.2009.12.004

Techniques in Regional Anesthesia & Pain Management
Volume 14, Issue 1 , Pages 10-18 , January 2010

Article Tools

* Image Usage & Resolution